Imunon (NASDAQ:IMNN – Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.
Imunon Price Performance
IMNN stock opened at $0.81 on Friday. The stock has a market capitalization of $11.91 million, a PE ratio of -0.43 and a beta of 1.75. The company has a 50 day moving average price of $0.90 and a 200 day moving average price of $0.88. Imunon has a fifty-two week low of $0.64 and a fifty-two week high of $3.65.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on the stock. D. Boral Capital restated a “buy” rating and set a $29.00 target price on shares of Imunon in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Imunon in a report on Wednesday, March 26th.
Imunon Company Profile
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Read More
- Five stocks we like better than Imunon
- What is the Nasdaq? Complete Overview with History
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Here’s The Reason Goldman Sachs Is Bullish On MercadoLibre Stock
- Expert Stock Trading Psychology Tips
- Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
